Poor quality regulatory documents can impact drug development timelines and your company’s reputation. Multiple reviewers, tight timelines, and changing requirements contribute to poor document quality. Document authors are typically responsible for ensuring quality. These authors are usually in high demand, are high cost, and may not have the time, experience, or skill sets required to do a thorough quality review. By using Krystelis’s independent quality review services, you can increase the quality of clinical trial documents while accelerating drug approval timelines and reducing costs.